{"data":[{"accessionNo":"0001193125-26-226565","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001658551","issuerName":"Amylyx Pharmaceuticals, Inc.","ticker":"AMLX","cusip":"03237H101","securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2026-03-31","reportingPerson":"Joseph Edelman","reportingCik":null,"personType":"IN","sharesOwned":8284882,"percentOfClass":7.5,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/amlx"},{"accessionNo":"0001193125-26-226565","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001658551","issuerName":"Amylyx Pharmaceuticals, Inc.","ticker":"AMLX","cusip":"03237H101","securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2026-03-31","reportingPerson":"Perceptive Advisors LLC","reportingCik":null,"personType":"IA","sharesOwned":8284882,"percentOfClass":7.5,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/amlx"},{"accessionNo":"0001193125-26-226565","formType":"SCHEDULE 13G/A","amendmentNo":4,"issuerCik":"0001658551","issuerName":"Amylyx Pharmaceuticals, Inc.","ticker":"AMLX","cusip":"03237H101","securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2026-03-31","reportingPerson":"Perceptive Life Sciences Master Fund, Ltd.","reportingCik":null,"personType":"CO","sharesOwned":8284882,"percentOfClass":7.5,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/amlx"},{"accessionNo":"0000102909-26-000598","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001658551","issuerName":"Amylyx Pharmaceuticals Inc","ticker":"AMLX","cusip":"03237H101","securityClass":"Common Stock","eventDate":"2026-03-13","reportingPerson":"The Vanguard Group","reportingCik":null,"personType":"IA","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-03-26","canonicalUrl":"https://xoomar.com/markets/stocks/amlx"},{"accessionNo":"0001193125-26-054741","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001658551","issuerName":"Amylyx Pharmaceuticals Inc.","ticker":"AMLX","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2025-12-31","reportingPerson":"TCG Crossover GP II, LLC","reportingCik":null,"personType":"OO","sharesOwned":6243812,"percentOfClass":5.7,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/amlx"},{"accessionNo":"0001193125-26-054741","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001658551","issuerName":"Amylyx Pharmaceuticals Inc.","ticker":"AMLX","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2025-12-31","reportingPerson":"TCG Crossover Fund II, L.P.","reportingCik":null,"personType":"PN","sharesOwned":6243812,"percentOfClass":5.7,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/amlx"},{"accessionNo":"0001193125-26-054741","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001658551","issuerName":"Amylyx Pharmaceuticals Inc.","ticker":"AMLX","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2025-12-31","reportingPerson":"Chen Yu","reportingCik":null,"personType":"IN","sharesOwned":6243812,"percentOfClass":5.7,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/amlx"},{"accessionNo":"0000902664-26-000907","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001658551","issuerName":"Amylyx Pharmaceuticals, Inc.","ticker":"AMLX","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2025-12-31","reportingPerson":"Adage Capital Management, L.P.","reportingCik":null,"personType":"IA,PN","sharesOwned":2777055,"percentOfClass":2.53,"filedAt":"2026-02-12","canonicalUrl":"https://xoomar.com/markets/stocks/amlx"},{"accessionNo":"0000902664-26-000907","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001658551","issuerName":"Amylyx Pharmaceuticals, Inc.","ticker":"AMLX","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2025-12-31","reportingPerson":"Robert Atchinson","reportingCik":null,"personType":"HC,IN","sharesOwned":2777055,"percentOfClass":2.53,"filedAt":"2026-02-12","canonicalUrl":"https://xoomar.com/markets/stocks/amlx"},{"accessionNo":"0000902664-26-000907","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001658551","issuerName":"Amylyx Pharmaceuticals, Inc.","ticker":"AMLX","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2025-12-31","reportingPerson":"Phillip Gross","reportingCik":null,"personType":"HC,IN","sharesOwned":2777055,"percentOfClass":2.53,"filedAt":"2026-02-12","canonicalUrl":"https://xoomar.com/markets/stocks/amlx"},{"accessionNo":"0000315066-26-000374","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001658551","issuerName":"AMYLYX PHARMACEUTICALS INC","ticker":"AMLX","cusip":null,"securityClass":"COMMON STOCK","eventDate":"2025-12-31","reportingPerson":"FMR LLC","reportingCik":null,"personType":"HC","sharesOwned":16468419,"percentOfClass":15,"filedAt":"2026-02-05","canonicalUrl":"https://xoomar.com/markets/stocks/amlx"},{"accessionNo":"0000315066-26-000374","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001658551","issuerName":"AMYLYX PHARMACEUTICALS INC","ticker":"AMLX","cusip":null,"securityClass":"COMMON STOCK","eventDate":"2025-12-31","reportingPerson":"Abigail P. Johnson","reportingCik":null,"personType":"IN","sharesOwned":16468419,"percentOfClass":15,"filedAt":"2026-02-05","canonicalUrl":"https://xoomar.com/markets/stocks/amlx"},{"accessionNo":"0000102909-26-000077","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001658551","issuerName":"Amylyx Pharmaceuticals Inc","ticker":"AMLX","cusip":null,"securityClass":"Common Stock","eventDate":"2025-12-31","reportingPerson":"The Vanguard Group","reportingCik":null,"personType":"IA","sharesOwned":5804912,"percentOfClass":5.28,"filedAt":"2026-01-30","canonicalUrl":"https://xoomar.com/markets/stocks/amlx"},{"accessionNo":"0002012383-26-000638","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001658551","issuerName":"Amylyx Pharmaceuticals, Inc.","ticker":"AMLX","cusip":null,"securityClass":"Common Stock","eventDate":"2025-12-31","reportingPerson":"BlackRock, Inc.","reportingCik":null,"personType":"HC","sharesOwned":7783648,"percentOfClass":7.1,"filedAt":"2026-01-21","canonicalUrl":"https://xoomar.com/markets/stocks/amlx"},{"accessionNo":"0001831942-25-000033","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001658551","issuerName":"Amylyx Pharmaceuticals, Inc.","ticker":"AMLX","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2025-11-10","reportingPerson":"Commodore Capital Master LP","reportingCik":null,"personType":"PN","sharesOwned":5650000,"percentOfClass":5.1,"filedAt":"2025-11-17","canonicalUrl":"https://xoomar.com/markets/stocks/amlx"},{"accessionNo":"0001831942-25-000033","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001658551","issuerName":"Amylyx Pharmaceuticals, Inc.","ticker":"AMLX","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2025-11-10","reportingPerson":"Commodore Capital LP","reportingCik":null,"personType":"IA,PN","sharesOwned":5650000,"percentOfClass":5.1,"filedAt":"2025-11-17","canonicalUrl":"https://xoomar.com/markets/stocks/amlx"},{"accessionNo":"0001831942-25-000033","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001658551","issuerName":"Amylyx Pharmaceuticals, Inc.","ticker":"AMLX","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2025-11-10","reportingPerson":"Robert Egen Atkinson","reportingCik":null,"personType":"HC,IN","sharesOwned":5650000,"percentOfClass":5.1,"filedAt":"2025-11-17","canonicalUrl":"https://xoomar.com/markets/stocks/amlx"},{"accessionNo":"0001831942-25-000033","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001658551","issuerName":"Amylyx Pharmaceuticals, Inc.","ticker":"AMLX","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2025-11-10","reportingPerson":"Michael Kramarz","reportingCik":null,"personType":"HC,IN","sharesOwned":5650000,"percentOfClass":5.1,"filedAt":"2025-11-17","canonicalUrl":"https://xoomar.com/markets/stocks/amlx"},{"accessionNo":"0001193125-25-282838","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001658551","issuerName":"Amylyx Pharmaceuticals, Inc.","ticker":"AMLX","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2025-09-30","reportingPerson":"Perceptive Advisors LLC","reportingCik":null,"personType":"IA","sharesOwned":8952365,"percentOfClass":8.2,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/amlx"},{"accessionNo":"0001193125-25-282838","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001658551","issuerName":"Amylyx Pharmaceuticals, Inc.","ticker":"AMLX","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2025-09-30","reportingPerson":"Joseph Edelman","reportingCik":null,"personType":"IN","sharesOwned":8952365,"percentOfClass":8.2,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/amlx"},{"accessionNo":"0001193125-25-282838","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001658551","issuerName":"Amylyx Pharmaceuticals, Inc.","ticker":"AMLX","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2025-09-30","reportingPerson":"Perceptive Life Sciences Master Fund, Ltd.","reportingCik":null,"personType":"CO","sharesOwned":8952365,"percentOfClass":8.2,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/amlx"},{"accessionNo":"0000902664-25-005011","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001658551","issuerName":"Amylyx Pharmaceuticals, Inc.","ticker":"AMLX","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-09-30","reportingPerson":"Point72 Asset Management, L.P.","reportingCik":null,"personType":"PN","sharesOwned":2801636,"percentOfClass":2.6,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/amlx"},{"accessionNo":"0000902664-25-005011","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001658551","issuerName":"Amylyx Pharmaceuticals, Inc.","ticker":"AMLX","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-09-30","reportingPerson":"Point72 Capital Advisors, Inc.","reportingCik":null,"personType":"CO","sharesOwned":2801636,"percentOfClass":2.6,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/amlx"},{"accessionNo":"0000902664-25-005011","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001658551","issuerName":"Amylyx Pharmaceuticals, Inc.","ticker":"AMLX","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-09-30","reportingPerson":"Steven A. Cohen","reportingCik":null,"personType":"IN","sharesOwned":2801636,"percentOfClass":2.6,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/amlx"},{"accessionNo":"0000902664-25-004887","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001658551","issuerName":"Amylyx Pharmaceuticals, Inc.","ticker":"AMLX","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2025-09-30","reportingPerson":"Adage Capital Management, L.P.","reportingCik":null,"personType":"IA,PN","sharesOwned":6816828,"percentOfClass":6.39,"filedAt":"2025-11-13","canonicalUrl":"https://xoomar.com/markets/stocks/amlx"},{"accessionNo":"0000902664-25-004887","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001658551","issuerName":"Amylyx Pharmaceuticals, Inc.","ticker":"AMLX","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2025-09-30","reportingPerson":"Robert Atchinson","reportingCik":null,"personType":"HC,IN","sharesOwned":6816828,"percentOfClass":6.39,"filedAt":"2025-11-13","canonicalUrl":"https://xoomar.com/markets/stocks/amlx"},{"accessionNo":"0000902664-25-004887","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001658551","issuerName":"Amylyx Pharmaceuticals, Inc.","ticker":"AMLX","cusip":null,"securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2025-09-30","reportingPerson":"Phillip Gross","reportingCik":null,"personType":"HC,IN","sharesOwned":6816828,"percentOfClass":6.39,"filedAt":"2025-11-13","canonicalUrl":"https://xoomar.com/markets/stocks/amlx"},{"accessionNo":"0000102909-25-000074","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001658551","issuerName":"Amylyx Pharmaceuticals Inc","ticker":"AMLX","cusip":null,"securityClass":"Common Stock","eventDate":"2025-09-30","reportingPerson":"The Vanguard Group","reportingCik":null,"personType":"IA","sharesOwned":5273750,"percentOfClass":4.94,"filedAt":"2025-10-30","canonicalUrl":"https://xoomar.com/markets/stocks/amlx"},{"accessionNo":"0000315066-25-002303","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001658551","issuerName":"AMYLYX PHARMACEUTICALS INC","ticker":"AMLX","cusip":null,"securityClass":"COMMON STOCK","eventDate":"2025-09-30","reportingPerson":"FMR LLC","reportingCik":null,"personType":"HC","sharesOwned":11379207,"percentOfClass":10.7,"filedAt":"2025-10-07","canonicalUrl":"https://xoomar.com/markets/stocks/amlx"},{"accessionNo":"0000315066-25-002303","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001658551","issuerName":"AMYLYX PHARMACEUTICALS INC","ticker":"AMLX","cusip":null,"securityClass":"COMMON STOCK","eventDate":"2025-09-30","reportingPerson":"Abigail P. Johnson","reportingCik":null,"personType":"IN","sharesOwned":11379207,"percentOfClass":10.7,"filedAt":"2025-10-07","canonicalUrl":"https://xoomar.com/markets/stocks/amlx"}],"updatedAt":"2026-11-03T19:36:46.912Z","source":"xoomar.com","docs":"https://xoomar.com/markets/api","license":"https://xoomar.com/terms","attribution":"Credit XOOMAR with a link to the dataset page on xoomar.com when you republish this data","canonicalUrl":"https://xoomar.com/markets/stocks/amlx","meta":{"source":"SEC","sourceAttribution":"Schedule 13D and 13G data: SEC.","notice":"10 requests a minute without a key, 30 with a free key. Get a free key at https://xoomar.com/signup?utm_source=api, register your app at https://xoomar.com/developers/register?utm_source=api, and credit the data as \"Data: XOOMAR\" together with the sourceAttribution line."}}